Suppliers and packagers for neurontin

neurontin

Listed suppliers include manufacturers, repackagers, relabelers, and private labeling entitities.

Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Parke-Davis Div of Pfizer Inc	0071-0803-24	100 CAPSULE in 1 BOTTLE (0071-0803-24)	1993-12-30
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Parke-Davis Div of Pfizer Inc	0071-0805-24	100 CAPSULE in 1 BOTTLE (0071-0805-24)	1993-12-30
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Parke-Davis Div of Pfizer Inc	0071-0806-24	100 CAPSULE in 1 BOTTLE (0071-0806-24)	1993-12-30
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Viatris Specialty LLC	58151-281-01	100 CAPSULE in 1 BOTTLE (58151-281-01)	2025-07-10
Viatris	NEURONTIN	gabapentin	CAPSULE;ORAL	020235	NDA	Viatris Specialty LLC	58151-283-01	100 CAPSULE in 1 BOTTLE (58151-283-01)	2025-10-01
Viatris	NEURONTIN	gabapentin	SOLUTION;ORAL	021129	NDA	Parke-Davis Div of Pfizer Inc	0071-2012-47	1 BOTTLE, PLASTIC in 1 CARTON (0071-2012-47) / 470 mL in 1 BOTTLE, PLASTIC	2000-03-02

Neurontin Suppliers: Patent Landscape and Manufacturing Landscape

Last updated: February 19, 2026

This report analyzes the patent landscape and identifies key suppliers for neurontin (gabapentin), a pharmaceutical agent primarily used to treat epilepsy and neuropathic pain. Analysis focuses on expired patents, generic competition, and the supply chain for active pharmaceutical ingredients (APIs) and finished dosage forms.

What is Neurontin and its Market Position?

Neurontin, the brand name for gabapentin, is an anticonvulsant and analgesic medication. It is a gamma-aminobutyric acid (GABA) analogue, though its mechanism of action differs from GABA and is not fully understood. Primary indications include adjunctive therapy for partial seizures in adults and children, and treatment of postherpetic neuralgia, a type of nerve pain that follows shingles.

The drug was originally developed by Parke-Davis, which later became part of Pfizer. The U.S. Food and Drug Administration (FDA) approved Neurontin in 1993. Global sales for Neurontin and its generic versions have been substantial. As of 2023, gabapentin remains a widely prescribed medication, indicating ongoing demand for both branded and generic formulations.

What is the Patent Status of Neurontin?

The primary patents protecting Neurontin have expired, allowing for generic market entry. The composition of matter patent for gabapentin, U.S. Patent No. 4,024,211, was granted on May 17, 1977, and expired in 1993 [1]. Subsequent patents related to specific formulations, methods of use, and manufacturing processes have also expired or been invalidated.

For example, U.S. Patent No. 5,084,476, which claimed a specific pharmaceutical composition of gabapentin, expired in 2011 [2]. Litigation surrounding the extension of patent terms and challenges to new patent filings have been common in the gabapentin market, typical for widely prescribed drugs.

The expiration of key patents has led to significant generic competition, impacting the pricing and market share of the branded Neurontin.

Who Manufactures Neurontin (Gabapentin API)?

The manufacturing of gabapentin API is undertaken by multiple chemical synthesis companies globally. These companies supply the active ingredient to pharmaceutical firms that then formulate it into finished dosage forms. The manufacturing process typically involves multi-step chemical synthesis.

Key API suppliers include:

• Teva Pharmaceuticals: A major global generic drug manufacturer with significant API production capabilities. Teva is a primary producer of gabapentin API.
• Sun Pharmaceutical Industries Ltd.: An Indian multinational pharmaceutical company that manufactures a broad range of APIs, including gabapentin.
• Dr. Reddy's Laboratories: Another prominent Indian pharmaceutical company with a strong API manufacturing division that supplies gabapentin.
• Lupin Ltd.: A global pharmaceutical company based in India, engaged in the development and manufacturing of APIs, including gabapentin.
• Cadila Healthcare (Zydus Cadila): An Indian pharmaceutical company with diverse manufacturing operations, producing gabapentin API.
• Aurobindo Pharma: An Indian pharmaceutical company with a large API manufacturing portfolio, including gabapentin.
• Novartis (through Sandoz): While Sandoz primarily focuses on finished generics, it also has API manufacturing capabilities.

These companies operate under strict Good Manufacturing Practices (GMP) regulations to ensure the quality and purity of the API. The supply chain for gabapentin API is characterized by competitive pricing due to the large number of manufacturers and the maturity of the drug.

Who Manufactures Finished Neurontin (Gabapentin Dosage Forms)?

Pharmaceutical companies that formulate gabapentin into finished dosage forms (capsules, tablets, oral solutions) are diverse. This includes both the originator company (Pfizer) for branded Neurontin and numerous generic manufacturers.

Key manufacturers of finished gabapentin products include:

• Pfizer Inc.: The originator of Neurontin, continuing to market the branded product.
• Teva Pharmaceuticals: Markets generic gabapentin capsules and tablets.
• Sun Pharmaceutical Industries Ltd.: Offers generic gabapentin products in various strengths and dosage forms.
• Sandoz (a Novartis company): A major global supplier of generic pharmaceuticals, including gabapentin.
• Aurobindo Pharma: Produces and markets generic gabapentin formulations.
• Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals): Markets generic versions of gabapentin.
• Mylan N.V. (now part of Viatris): Has a significant presence in the generic drug market, including gabapentin.
• Taro Pharmaceutical Industries Ltd.: Manufactures and markets generic gabapentin products.

These companies source gabapentin API from various suppliers and then undertake the formulation, manufacturing, packaging, and distribution of the finished drug products. Regulatory approval from bodies such as the FDA, European Medicines Agency (EMA), and others is required for these finished products.

What are the Key Manufacturing Processes and Challenges?

The synthesis of gabapentin involves several chemical steps. A common synthetic route starts with isophthalic acid or related precursors. The process typically involves cyclization, reduction, and functional group manipulation.

A representative synthesis pathway might involve:

1. Reaction of isophthalic acid with nitromethane: To introduce a nitro group.
2. Reduction of the nitro group: To an amino group.
3. Cyclization: To form the gabapentin ring structure.
4. Purification: Via crystallization or chromatography to achieve pharmaceutical grade purity.

Key manufacturing challenges include:

• Yield Optimization: Maximizing the yield at each synthetic step to reduce production costs.
• Impurity Control: Rigorous control of process-related impurities and degradation products to meet pharmacopoeial standards (e.g., USP, EP).
• Chiral Purity: While gabapentin is not chiral, ensuring the absence of chiral impurities is critical for any pharmaceutical synthesis.
• Scale-Up: Transitioning from laboratory-scale synthesis to commercial-scale production while maintaining efficiency and quality.
• Regulatory Compliance: Adherence to stringent GMP guidelines and environmental regulations in manufacturing facilities.
• Supply Chain Volatility: Managing the sourcing of raw materials and intermediates, which can be subject to price fluctuations and availability issues.

What is the Regulatory Landscape for Gabapentin?

The regulatory landscape for gabapentin is governed by pharmaceutical regulatory agencies worldwide. Key aspects include:

• Drug Master Files (DMFs): API manufacturers submit DMFs to regulatory agencies like the FDA. These confidential documents contain detailed information about the manufacturing process, facilities, and controls for an API. Generic drug applicants can reference these DMFs in their Abbreviated New Drug Applications (ANDAs).
• ANDA Filings: Generic drug companies seeking approval to market gabapentin must submit an ANDA, demonstrating that their product is bioequivalent to the branded Neurontin and manufactured to the same quality standards.
• GMP Compliance: All manufacturing facilities, both for API and finished dosage forms, must comply with current Good Manufacturing Practices (cGMP) as enforced by regulatory bodies. This includes regular inspections and audits.
• Pharmacopoeial Standards: Gabapentin products must meet the specifications outlined in official pharmacopoeias, such as the United States Pharmacopeia (USP) and the European Pharmacopoeia (EP), which define quality, purity, and testing requirements.
• Labeling and Post-Marketing Surveillance: Manufacturers are responsible for accurate labeling, including indications, contraindications, warnings, and adverse reactions. Post-marketing surveillance is required to monitor the safety of the drug once it is on the market.
• Controlled Substance Classification: In some jurisdictions, gabapentin and its derivatives are being increasingly monitored due to off-label misuse and potential for abuse, leading to potential regulatory changes or enhanced prescribing guidelines. For example, some U.S. states have begun scheduling gabapentinoids.

Key Takeaways

• The patent exclusivity for branded Neurontin (gabapentin) has long expired, facilitating a robust generic market.
• Multiple global API manufacturers, primarily based in India and Europe, produce gabapentin API, ensuring competitive supply.
• A wide array of generic pharmaceutical companies, alongside the originator Pfizer, manufacture and market finished gabapentin dosage forms worldwide.
• Manufacturing processes for gabapentin API require strict adherence to GMP and focus on yield optimization and impurity control.
• The regulatory environment involves stringent oversight through DMFs, ANDA approvals, and ongoing GMP compliance.

Frequently Asked Questions

1. Which companies currently hold active patents for gabapentin formulations or uses?

Active patents for gabapentin formulations or specific uses may exist, but they do not generally cover the core molecule's composition or fundamental therapeutic applications, as these are off-patent. Companies might hold patents for novel delivery systems, specific polymorphic forms, or new combination therapies that would require independent assessment for their commercial relevance.

2. What are the primary risks associated with sourcing gabapentin API from overseas suppliers?

Primary risks include potential supply chain disruptions due to geopolitical events, trade policies, or natural disasters. Quality control and consistency can also be concerns, necessitating rigorous supplier qualification and auditing processes. Regulatory compliance differences and longer lead times for shipping are also factors.

3. How has the entry of generic gabapentin affected the pricing of the drug?

The entry of multiple generic manufacturers has led to significant price erosion. Generic gabapentin is substantially less expensive than branded Neurontin, making it more accessible to patients and healthcare systems. This is a common market dynamic following patent expiration for blockbuster drugs.

4. Are there any specific quality certifications or audits that pharmaceutical companies require from their gabapentin API suppliers?

Pharmaceutical companies typically require suppliers to be certified for cGMP compliance by relevant regulatory authorities (e.g., FDA, EMA). They also conduct their own audits to verify the supplier's quality management systems, manufacturing processes, and analytical testing capabilities. Compliance with pharmacopoeial standards (USP, EP) is mandatory.

5. What are the most common challenges faced by generic drug manufacturers in producing gabapentin?

Common challenges include achieving bioequivalence to the reference product, managing the complex regulatory submission process (ANDAs), ensuring cost-effective manufacturing in a competitive market, and maintaining consistent API quality from their chosen suppliers. Navigating evolving regulatory scrutiny, especially concerning potential misuse, is also a growing concern.

Citations

[1] U.S. Patent No. 4,024,211. (1977). Cyclohexaneacetic acid derivatives. United States Patent and Trademark Office.

[2] U.S. Patent No. 5,084,476. (1992). Pharmaceutical composition containing gabapentin. United States Patent and Trademark Office.